CURRENT Medical Diagnosis and Treatment 2023-McGraw Hill


Download CURRENT Medical Diagnosis and Treatment 2023-McGraw Hill  Easily In PDF Format For Free



  Current Medical Diagnosis & Treatment 2023 (CMDT 2023) is the 62nd edition of this single-source reference for
practitioners of adult medicine in both hospital and ambulatory settings. The book emphasizes the practical features of
clinical diagnosis and patient management in all fields of internal medicine and in specialties of interest to primary care
practitioners and to subspecialists who provide general care.

With a growing recognition of systemic racism and other biases in institutions across our societies, including the institu-
tion of medicinethe editors of CMDT, with humility, have committed to a thorough

examination of our content to remove biased language, research, and recommendations. Since 2020, we have been pursuing
an ongoing, formal process of review and revision in an effort to recognize and correct biases and to promote equity in our
book and the practice of medicine. While we, the editors, take this on as our responsibility, we also invite readers to share
with us any CMDT content that they find problematic or biased.

We have tried to describe populations used in the studies that form the basis of the information in CMDT, use appropri-
ate language where we can (eg, persons of sub-Sahara African descent, rather than African-Americans), and use the gender-
neutral term Latinx. We acknowledge that, like others,1 we find this an imperfect solution. We continue, however, to use

terms from original sources when study populations are broad.


 House officers, medical students, and all other health professions students will find the descriptions of diagnostic and
therapeutic modalities, with citations to the current literature, of everyday usefulness in patient care.
Internists, family physicians, hospitalists, nurse practitioners, physician assistants, and all primary care providers of
adult medicine will appreciate CMDT as a ready reference and refresher text. Physicians in other specialties, pharmacists,
and dentists will find the book a useful basic medical reference text. Nurses, nurse practitioners, and physician assistants
will welcome the format and scope of the book as a means of quickly referencing medical diagnosis and treatment
Patients and their family members who seek information about the nature of specific diseases and their diagnosis and
treatment may also find this book to be a valuable resource.



  • INNOVATIVE TABLE highlighting the “Year in Review: Key Clinical Updates in CMDT 2023,” individually listed
with page numbers and reference citations, for easy access to significant changes in this edition
• Ongoing concerted effort to address and remove unconscious bias • List of Common Abbreviations used in CMDT can be found on the inside of the front cover • New section on opioids for pain management • Overhauled organization of Dermatology chapter to better reflect categorization of conditions and lesions • Expanded section of interventional therapies to manage chronic pain
• Updated USPSTF lung cancer screening recommendations using low-dose CT
• New prognostic systems for primary myelofibrosis: GIPSS and MIPSSv2
• Discussion of the use of DOACs in patients with morbid obesity who require antithrombotic therapy
• Updated section on osmotic laxatives to treat chronic constipation
• Ozanimod approved for the treatment of moderate to severe ulcerative colitis • Landmark change in staging female breast carcinoma modifying anatomic stage and adding prognostic stage
• New medications for treating metastatic breast cancer (olaparib, talazoparib, palbociclib, ribociclib, and abemaciclib) • New recommendations on treating cholestasis of pregnancy
• Updated criteria for diagnosing systemic lupus erythematosus to include antinuclear antibody measurement • New medications for active lupus nephritis, including voclosporin used with mycophenolate mofetil as well as belimumab
• Anifrolumab is approved for nonrenal lupus when standard therapies fail

 • New guidelines for diagnosing polyarteritis nodosa
• New American College of Rheumatology/Vasculitis Foundation recommendations for the treatment of granulomatosis

with polyangiitis • A newly described genetic syndrome, VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) in the dif-
ferential diagnosis of relapsing polychondritis • Discussion of the role of left atrial appendage closure in preventing stroke and systemic embolization

• Aducanumab (anti-amyloid therapy) is approved by the US FDA for the treatment of Alzheimer disease
• Extensive revision of the Thyroiditis section in Endocrine Disorders chapter • Substantial revision of the Nutritional Support section in the Nutritional Disorders & Obesity chapter • Substantial revision in the HIV Infection & AIDS chapter, including updates in the available therapeutic regimens • Rewritten SARS-CoV-2 section and inclusion of SARS-CoV-2 information relevant to specific chapters throughout the
• Extensive revision of Sexual & Gender Minority Health chapter, including sections on family planning and health care
for transgender and gender diverse persons



 • Medical advances up to time of annual publication
• Detailed presentation of internal medicine disciplines, plus primary care topics in gynecology, obstetrics, dermatology,
ophthalmology, otolaryngology, psychiatry, neurology, toxicology, urology, geriatrics, orthopedics, women’s health,
sexual and gender minority health, preventive medicine, and palliative care
• Concise format, facilitating efficient use in any practice setting
• More than 1000 diseases and disorders • Specific disease prevention information
• Easy access to medication dosages, with trade names indexed and current costs updated in each annual edition
• Recent references, with unique identifiers (PubMed, PMID numbers) for rapid downloading of article abstracts and, in
some instances, full-text reference articles




Font Size
lines height